Desktop Site
|
19 Apr 24 | 16:00
|
Close
Equity
SME
Eq Drv
Currency
Commodity
Corporates
Get Quote
*
Notices
|
S&P
BSE SENSEX
73,088.33
+599.34
+0.83 %
Corporate Announcement
Security Code
532296
Company
Glenmark Pharmaceuticals Ltd
Exchange Received Time
14/12/2017 09:09:29
Exchange Disseminated Time
14/12/2017 09:09:33
Time Taken
00:00:04
Press Release / Media Release |
12/14/2017 9:09:30 AM
December 14, 2017
Dear Sirs,
Sub: Glenmark Pharmaceuticals Announces Top-Line Results from a Phase 3 Safety Study Evaluating Ryaltris™ in Patients with Perennial Allergic Rhinitis
With reference to the subject mentioned above, kindly find attached media release which is self-explanatory.
Request you to kindly take the same on record.
Thanking you,
Yours faithfully,
For Glenmark Pharmaceuticals Limited
Harish Kuber
Company Secretary & Compliance Officer
Attachment
<< Back
Recently Viewed